Dozens of U.S. ice cream makers pledge to eliminate artificial colors
July 15 (UPI) -- Dozens of U.S. ice cream manufacturers are pledging to eliminate the use of artificial food colors from their ice cream products made with real milk by the end of 2027, the U.S. dairy manufacturing and marketing trade association said.
Announced Monday by the International Dairy Foods Association, the companies have agreed to remove certified artificial colors Red No. 3, Red No. 40, Green No. 3, Blue No. 1, Blue No. 2, Yellow No. 5 and Yellow No. 6 from their frozen dairy products by 2028.
According to the dairy trade association, the commitment is from companies that together make more than 90% of the ice cream sold in the United States.
"Americans are passionate about their ice cream, and the IDFA Ice Cream Commitment will ensure wholesome, indulgent ice cream products made with real milk from American dairy farmers remain a special part of our lives as state and federal policies evolve," Michael Dykes, president and CEO of IDFA, said in a statement.
The announcement comes as the Food and Drug Administration has been seeking to remove artificial food colorings from the U.S. market.
During the final days of the previous Biden administration, the FDA announced it had revoked authorization for the use of synthetic food dye Red No. 3 after a linkage to cancer was found in animal studies, with its use to be phased out by 2028.
Under the Trump administration, the FDA announced in April plans to phase out petroleum-based dyes, including those U.S. ice cream makers pledged Monday to eliminate from their products.
"These poisonous compounds offer no nutritional benefit and pose real, measurable dangers to our children's health and development," Department of Health and Human Services Secretary Robert F. Kennedy Jr. said in a statement making the announcement. "That era is coming to an end."
While phasing out artificial color dyes, the FDA has been approving natural color additives, announcing the authorization of galdieria extract blue, butterfly pea flower extract and calcium phosphate, in May.
The FDA also approved the use of a new blue color additive from the gardenia fruit on Monday.
The IDFA said the Monday commitment from U.S. ice cream makers only applies to products made with real milk sold at food retail and does not apply to products made with non-dairy ingredients or those made in-house by small ice cream shops or restaurants.
On Friday, the Consumer Brands Association announced a voluntary commitment to encourage U.S. food and beverage makers to remove certified Food, Drug and Cosmetic colors from products served in schools nationwide by the start of the 2026-27 school year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan
Key Takeaways Shares of drug developer Sarepta Therapeutics jumped in extended trading Wednesday after the company unveiled a major restructuring plan. The plan involves cutting 36% of its workforce and pausing several programs in its pipeline. Sarepta's stock has cratered this year after two patients taking its Elevidys drug for Duchenne muscular dystrophy died of acute liver of struggling drug developer Sarepta Therapeutics (SRPT) skyrocketed nearly 40% in extended trading Wednesday after the company unveiled a major restructuring plan. The company said it will slash its workforce by 36%, or roughly 500 employees, in order to to generate $100 million in annual cost savings starting in 2026. Another $300 million is expected to come from pausing several programs in its drug development pipeline. Sarepta's stock has collapsed this year after two patients taking its Elevidys drug for Duchenne muscular dystrophy died of acute liver failure. Through Wednesday's close, its shares were down 85% from the start of the year. Sarepta said it agreed to a Food and Drug Administration request to introduce a black box warning label for Elevidys covering acute liver injury and acute liver failure. Sarepta posted preliminary net product revenue of $513 million for the second quarter, of which $282 million came from Elevidys. The company is expected to release its full results for the second quarter in early August. Read the original article on Investopedia Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
UPI
an hour ago
- UPI
FDA to end dozens of 'obsolete' rules for U.S. food items
"I'm eliminating outdated food regulations that no longer serve the interests of American families," U.S. Health and Human Services Secretary Robert F. Kennedy Jr. (pictured July 15 at the U.S. Capitol in Washington, D.C.) said Wednesday. Photo by Bonnie Cash/UPI | License Photo July 16 (UPI) -- The federal government says its ending a whole slew of "obsolete" U.S. food standards that Trump administration officials say also include "unnecessary" ones. "I'm eliminating outdated food regulations that no longer serve the interests of American families," stated U.S. Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday. The U.S. Food and Drug Administration announced that it's revoking, or proposing to revoke, 52 federal standards for scores of food products in items such as canned fruit, vegetables, dairy, baked goods and macaroni products. It will also apply to areas of food safety, packaging, manufacturing and production practices and nutrition information, labeling and claims on American-made products. A proposal targets 23 types of product -- bakery, noodle and macaroni products, canned fruit juices, fish and shellfish along with flavoring and food dressings. Kennedy said his new U.S. food policy changes marked a "crucial step in my drive to cut through bureaucratic red tape, increase transparency and remove regulations that have outlived their purpose." In March he had ordered the FDA to revise its rule allowing food companies to "self-affirm" the safety of its own ingredients. FDA officials say Wednesday's unveiling is the first round of results in the ongoing review of its portfolio of over 250 "Standards on Identity," with a goal to "make sure they are useful, relevant and serve consumers." "Antiquated food standards are no longer serving to protect consumers. It is common sense to revoke them and move to a more judicious use of food standards and agency resources," said FDA Commissioner Marty Makary. The Food and Drug Administration now contends that additional consumer protections mixed with advances in food science, production and agricultural practices have made it "unnecessary" to keep many of the older "recipe standards." A direct rule, which came with a proposed companion in case of a legal challenge, ends federal guidance and standards on 11 types of canned fruits and vegetables the FDA claimed is "no longer sold in U.S. grocery stores." It included seven rules for artificially-sweetened fruits with saccharin or sodium saccharin. The other proposed revocation of standards looks at 18 dairy product types to included certain milk and cream items, frozen desserts, cheese and cheese-related products. "The removal of these standards is in alignment with broader efforts to ensure that HHS is directing resources to where they're most needed," which federal officials say is in "delivering better outcomes for the American people." For example, an FDA analysis concluded that "little to no market" existed for dairy products like Goat's milk ice cream, acidified milk and acidified sour cream. It also included a plethora of cheese lines: Caciocavallo siliciano, Low sodium cheddar, Low sodium colby, Cook cheese, koch kaese, Gammelost, High-moisture jack, Nuworld, Samsoe, Mellorine and Sap sago cheese. In 1939, the U.S. government created food standards for a multitude of consumer and public health-related reasons part of massive social changes that took place under the administration of then-President Franklin D. Roosevelt. Kennedy's FDA under HHS argued that "many" of the "outdated and unnecessary" federal standards predate later requirements on American consumer protections on public issues such as ingredient safety and labeling. "Because few products covered by these food standards are currently marketed, revoking these 13 food standards would affect few small businesses," according to government officials. The agency claimed that with these changes, small businesses as a result may see "benefits of additional flexibility in product development."
Boston Globe
an hour ago
- Boston Globe
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting
Advertisement While painful, investors viewed the restructuring as a positive move ensuring the company would survive the recent string of bad news. Sarepta's stock price rose more than 50 percent to $28 per share in Wednesday's after-hours trading session. The stock closed the day at $18 per share, down 85 percent this year and a nine-year low. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up At its peak, the gene therapy, Elevidys, was projected to bring in over $3 billion per year. Now, the company has pulled it off the market for any Duchenne patients who use wheelchairs — most children and young adults with the condition over the age of 12. Elevidys remains available for younger Duchenne patients who can still walk, but Sarepta management has conceded that safety concerns are causing physicians and families to proceed with more caution, forcing the company to withdraw its sales forecast. Advertisement CEO Doug Ingram said in May the company would work to make the therapy available again for all patients, with improved protocols to mitigate safety concerns. But it likely faces an uphill battle, particularly given the Food and Drug Administration's new leadership. Vinay Prasad, director of the division that regulates gene therapies said in March, before his appointment, that Elevidys 'doesn't work but kills kids.' On Wednesday, the company said it will discuss with the FDA its plan to test the new protocol in a new cohort of an ongoing clinical trial, before trying to make Elevidys available again for older patients. At the FDA's request, Sarepta has agreed to add a so-called 'black box' safety warning to the Elevidys prescribing label, warning physicians about the risk of acute liver injury and liver failure associated with the gene therapy. Competition also looms. Two other gene therapies from rival companies are nearing approval. So are newer, more targeted versions of the company's so-called exon-skipping drugs, which have earned Sarepta over $4 billion despite little data showing they slow the progression of Duchenne. The company discontinued its own efforts at next-generation skippers over safety concerns. In its announcement, Sarepta said it will invest further in bringing forward a series of RNA medicines it recently licensed as it tries to chart a new future.
